7497 | Humans |
5206 | Male |
4834 | Female |
3893 | Middle Aged |
3346 | Parkinson Disease |
3333 | Aged |
2523 | Adult |
959 | Severity of Illness Index |
945 | Magnetic Resonance Imaging |
942 | Aged, 80 and over |
893 | Antiparkinson Agents |
862 | Levodopa |
861 | Neurologic Examination |
738 | Brain |
621 | Dystonia |
576 | Electromyography |
570 | Treatment Outcome |
559 | Adolescent |
542 | Animals |
515 | Tremor |
499 | Movement Disorders |
472 | Neuropsychological Tests |
465 | Follow-Up Studies |
455 | Diagnosis, Differential |
425 | Parkinsonian Disorders |
399 | Deep Brain Stimulation |
377 | Case-Control Studies |
353 | Child |
347 | Cognition Disorders |
339 | Disease Progression |
331 | Dose-Response Relationship, Drug |
329 | Mutation |
327 | Questionnaires |
326 | Time Factors |
324 | Retrospective Studies |
298 | Dystonic Disorders |
298 | Dyskinesia, Drug-Induced |
293 | Young Adult |
289 | Analysis of Variance |
280 | Disability Evaluation |
278 | Corpus Striatum |
277 | Functional Laterality |
271 | Huntington Disease |
269 | Substantia Nigra |
268 | Myoclonus |
266 | Globus Pallidus |
259 | Double-Blind Method |
256 | Multiple System Atrophy |
255 | Subthalamic Nucleus |
252 | Risk Factors |
250 | Age of Onset |
243 | Chorea |
240 | Cerebral Cortex |
232 | Dopamine |
230 | Drug Therapy, Combination |
228 | Basal Ganglia |
226 | Tomography, Emission-Computed, Single-Photon |
222 | Electroencephalography |
220 | Brain Mapping |
219 | Essential Tremor |
216 | Reproducibility of Results |
214 | Genotype |
211 | Torticollis |
208 | DNA Mutational Analysis |
204 | Muscle, Skeletal |
200 | Phenotype |
199 | Psychomotor Performance |
199 | Dopamine Agonists |
197 | Supranuclear Palsy, Progressive |
197 | Quality of Life |
196 | Pedigree |
195 | Genetic Predisposition to Disease |
194 | Reaction Time |
194 | Parkinson Disease, Secondary |
191 | Videotape Recording |
189 | Motor Activity |
188 | Dominance, Cerebral |
185 | Neurons |
181 | Prospective Studies |
179 | Nerve Tissue Proteins |
179 | Dementia |
174 | Restless Legs Syndrome |
172 | Posture |
167 | Longitudinal Studies |
167 | Age Factors |
166 | Movement |
162 | Prevalence |
162 | Cohort Studies |
159 | Statistics, Nonparametric |
157 | Child, Preschool |
155 | Cross-Sectional Studies |
154 | alpha-Synuclein |
153 | Atrophy |
152 | Drug Administration Schedule |
150 | Reference Values |
150 | Botulinum Toxins, Type A |
150 | Activities of Daily Living |
148 | Cerebellum |
145 | Tomography, X-Ray Computed |
143 | Thalamus |
143 | Psychiatric Status Rating Scales |
141 | Gait Disorders, Neurologic |
139 | Disease Models, Animal |
139 | Basal Ganglia Diseases |
138 | Tourette Syndrome |
137 | Dopamine Agents |
137 | Botulinum Toxins |
135 | Electric Stimulation Therapy |
134 | Nerve Degeneration |
134 | Motor Cortex |
134 | Family Health |
133 | Gait |
132 | Antipsychotic Agents |
130 | Depression |
128 | Carbidopa |
127 | Image Processing, Computer-Assisted |
126 | Electrodes, Implanted |
123 | Dyskinesias |
120 | Point Mutation |
120 | Neural Pathways |
118 | Polysomnography |
113 | Positron-Emission Tomography |
112 | Putamen |
112 | Electric Stimulation |
110 | Sensitivity and Specificity |
109 | Motor Skills |
109 | Mental Status Schedule |
106 | Injections, Intramuscular |
106 | Blepharospasm |
105 | Brain Stem |
103 | Protein-Serine-Threonine Kinases |
102 | Gene Frequency |
102 | Anticonvulsants |
101 | Ubiquitin-Protein Ligases |
101 | Neurodegenerative Diseases |
101 | Frontal Lobe |
100 | History, 20th Century |
99 | Postural Balance |
98 | Statistics as Topic |
97 | Tomography, Emission-Computed |
96 | Pilot Projects |
95 | Predictive Value of Tests |
94 | Syndrome |
94 | Hand |
91 | Lewy Body Disease |
91 | Evoked Potentials, Motor |
90 | Neuromuscular Agents |
90 | Hypokinesia |
88 | United States |
87 | Spinocerebellar Ataxias |
87 | Exons |
85 | Radiopharmaceuticals |
83 | Transcranial Magnetic Stimulation |
83 | Cognition |
82 | Rats |
82 | Incidence |
82 | Genetic Testing |
82 | Dopamine Plasma Membrane Transport Proteins |
80 | Attention |
80 | Anti-Dyskinesia Agents |
80 | Alleles |
79 | Polymorphism, Single Nucleotide |
78 | Sex Factors |
78 | Polymorphism, Genetic |
76 | Hallucinations |
76 | Drug Combinations |
76 | Ataxia |
75 | Walking |
75 | Psychometrics |
75 | Chi-Square Distribution |
75 | Apomorphine |
74 | Tropanes |
74 | Regression Analysis |
73 | Cross-Over Studies |
73 | Cerebral Infarction |
72 | Spinal Cord |
72 | Receptors, Dopamine |
72 | Polymerase Chain Reaction |
72 | Nuclear Proteins |
72 | Mesencephalon |
72 | Evoked Potentials, Somatosensory |
71 | Muscle Rigidity |
71 | Motor Neurons |
71 | Biomechanical Phenomena |
70 | Postoperative Complications |
70 | Clinical Trials as Topic |
70 | Arm |
69 | Receptors, Dopamine D2 |
69 | REM Sleep Behavior Disorder |
69 | Pain |
69 | Infant |
68 | Lewy Bodies |
67 | Odds Ratio |
65 | Neuroprotective Agents |
65 | Neural Inhibition |
64 | Sleep Disorders |
63 | Video Recording |
63 | Trinucleotide Repeats |
63 | Trinucleotide Repeat Expansion |
63 | Neck Muscles |
63 | Mice |
63 | Hepatolenticular Degeneration |
63 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
62 | Comorbidity |
62 | Chromosome Aberrations |
62 | Autonomic Nervous System Diseases |
61 | Muscle Contraction |
61 | Mental Disorders |
61 | Fluorodeoxyglucose F18 |
61 | Cerebellar Ataxia |
61 | Caudate Nucleus |
60 | tau Proteins |
60 | Stereotaxic Techniques |
60 | Olfaction Disorders |
60 | Leg |
60 | Alzheimer Disease |
59 | Indoles |
59 | History, 19th Century |
59 | Blinking |
57 | Iodine Radioisotopes |
57 | Genes, Dominant |
57 | Combined Modality Therapy |
56 | Randomized Controlled Trials as Topic |
56 | Molecular Chaperones |
55 | Logistic Models |
55 | Fatal Outcome |
53 | Risk |
53 | Neurology |
52 | Dystonia Musculorum Deformans |
52 | Depressive Disorder |
51 | Signal Processing, Computer-Assisted |
51 | Pain Measurement |
50 | Psychotic Disorders |
50 | Outcome Assessment (Health Care) |
50 | Nerve Net |
50 | Biological Markers |
50 | Benzothiazoles |
49 | Pons |
49 | Neurosurgical Procedures |
49 | Membrane Glycoproteins |
49 | Facial Muscles |
49 | Brain Diseases |
48 | Spinocerebellar Degenerations |
48 | Bromocriptine |
47 | Sensation Disorders |
47 | Membrane Transport Proteins |
47 | Haplotypes |
47 | Genetic Linkage |
46 | Spasm |
46 | ROC Curve |
46 | Japan |
46 | Heterozygote Detection |
46 | Handwriting |
46 | Gene Expression |
46 | Demography |
45 | Selegiline |
45 | Glycine |
45 | Friedreich Ataxia |
45 | Databases, Factual |
44 | Iron |
44 | Fingers |
44 | Epilepsies, Myoclonic |
43 | Tyrosine 3-Monooxygenase |
43 | Recurrence |
43 | Pergolide |
43 | Muscles |
43 | Diffusion Magnetic Resonance Imaging |
43 | Athetosis |
42 | Smoking |
42 | Observer Variation |
42 | Linear Models |
42 | Health Status |
42 | Confidence Intervals |
42 | Accidental Falls |
41 | Thalamic Nuclei |
41 | Italy |
41 | Carrier Proteins |
40 | Stereotyped Behavior |
40 | Reflex, Abnormal |
40 | Imaging, Three-Dimensional |
40 | Genetic Variation |
40 | Cues |
40 | Acoustic Stimulation |
39 | Tic Disorders |
39 | Spain |
39 | Somatosensory Cortex |
39 | Single-Blind Method |
39 | Psychomotor Disorders |
39 | Prognosis |
39 | Mutation, Missense |
39 | Multiple Sclerosis |
39 | Magnetic Resonance Spectroscopy |
39 | Dopamine Antagonists |
39 | Clonazepam |
39 | Chromosome Mapping |
39 | Chromosome Disorders |
39 | Asian Continental Ancestry Group |
39 | Administration, Oral |
38 | gamma-Aminobutyric Acid |
38 | Periodicity |
38 | Locomotion |
38 | Heart Rate |
38 | Head Movements |
38 | Executive Function |
38 | Anxiety |
37 | Synaptic Transmission |
37 | RNA, Messenger |
37 | Parietal Lobe |
37 | Obsessive-Compulsive Disorder |
37 | Health Surveys |
37 | France |
37 | Ergolines |
37 | DNA-Binding Proteins |
37 | Aging |
36 | Reflex, Startle |
36 | Protein Kinases |
36 | Immunohistochemistry |
36 | Evoked Potentials |
36 | Dysarthria |
35 | Psychophysiologic Disorders |
35 | Photic Stimulation |
35 | Orientation |
35 | Ocular Motility Disorders |
35 | Microelectrodes |
35 | Machado-Joseph Disease |
35 | Genetic Markers |
34 | Ultrasonography, Doppler, Transcranial |
34 | Sleep Stages |
34 | Pyramidal Tracts |
34 | Pregnancy |
34 | Olivopontocerebellar Atrophies |
34 | Occupational Diseases |
34 | Music |
34 | Hyperkinesis |
34 | Europe |
34 | Dihydroxyphenylalanine |
34 | Amantadine |
33 | Stroke |
33 | Meige Syndrome |
33 | History, 21st Century |
33 | Autopsy |
32 | Speech Disorders |
32 | Serine |
32 | Proportional Hazards Models |
32 | Prefrontal Cortex |
32 | Injections, Subcutaneous |
32 | Heterozygote |
32 | Germany |
32 | Genetic Association Studies |
32 | Eye Movements |
32 | Disorders of Excessive Somnolence |
32 | Clozapine |
32 | Cerebrovascular Circulation |
32 | Arousal |
32 | Acute Disease |
31 | Synucleins |
31 | Reflex |
31 | Impulse Control Disorders |
31 | Hand Strength |
31 | European Continental Ancestry Group |
31 | Circadian Rhythm |
31 | 3-Iodobenzylguanidine |
30 | Visual Perception |
30 | Ventral Thalamic Nuclei |
30 | Substance Withdrawal Syndrome |
30 | Schizophrenia |
30 | Multivariate Analysis |
30 | Macaca fascicularis |
30 | Freezing Reaction, Cataleptic |
30 | Exercise |
30 | Discrimination (Psychology) |
30 | Deglutition Disorders |
30 | Callithrix |
30 | Benzamides |
30 | Autoantibodies |
29 | Tongue |
29 | Sarcoglycans |
29 | Rats, Sprague-Dawley |
29 | Neuronal Plasticity |
29 | Neural Conduction |
29 | Hemifacial Spasm |
29 | Head |
29 | Fatigue |
29 | Cerebellar Diseases |
29 | Biopsy |
29 | Antibodies |
28 | Tetrabenazine |
28 | Temporal Lobe |
28 | Smell |
28 | Proprioception |
28 | Mood Disorders |
28 | Monoamine Oxidase Inhibitors |
28 | Memory |
28 | Intracellular Signaling Peptides and Proteins |
28 | Indans |
28 | Gambling |
28 | Enzyme-Linked Immunosorbent Assay |
28 | Drug Tolerance |
28 | Cross-Cultural Comparison |
28 | Catechols |
28 | Blood Pressure |
28 | Apraxias |
28 | Action Potentials |
27 | Stereotypic Movement Disorder |
27 | Sensory Thresholds |
27 | Nitriles |
27 | Mass Screening |
27 | Chronic Disease |
27 | Cerebral Hemorrhage |
27 | Brain Neoplasms |
26 | Voice Disorders |
26 | Thiazoles |
26 | Piracetam |
26 | Perceptual Disorders |
26 | Oxidative Stress |
26 | Long-Term Care |
26 | Hypertension |
26 | Homozygote |
26 | Genes, Recessive |
26 | Epilepsy |
26 | Diagnostic Imaging |
26 | Brazil |
26 | Arginine |
26 | Affect |
25 | Treatment Failure |
25 | Thalamic Diseases |
25 | Phosphotransferases (Alcohol Group Acceptor) |
25 | Oxidopamine |
25 | Oncogene Proteins |
25 | Neck |
25 | Membrane Proteins |
25 | Median Nerve |
25 | MPTP Poisoning |
25 | International Cooperation |
25 | Hemiplegia |
25 | Heart |
25 | Energy Metabolism |
25 | Encephalitis |
25 | Emotions |
25 | Cocaine |
25 | Cell Count |
25 | Aspartic Acid |
24 | Sleep |
24 | Sleep, REM |
24 | Siblings |
24 | Serotonin Uptake Inhibitors |
24 | Physical Therapy Modalities |
24 | Peripheral Nervous System Diseases |
24 | Nocturnal Myoclonus Syndrome |
24 | Muscle Cramp |
24 | Intellectual Disability |
24 | Infusions, Intravenous |
24 | Great Britain |
24 | Glucose |
24 | Gene Deletion |
24 | Fragile X Syndrome |
24 | Extremities |
24 | Depressive Disorder, Major |
24 | DNA Primers |
24 | Constipation |
24 | Body Mass Index |
24 | Autonomic Nervous System |
24 | Attention Deficit Disorder with Hyperactivity |
24 | Amyloid beta-Peptides |
23 | Tics |
23 | Terminology as Topic |
23 | Stiff-Person Syndrome |
23 | Saccades |
23 | Pregnancy Complications |
23 | Palatal Muscles |
23 | Oxygen |
23 | Motor Neuron Disease |
23 | Mitochondria |
23 | Inclusion Bodies |
23 | Homovanillic Acid |
23 | Genome-Wide Association Study |
23 | Gene Expression Regulation |
23 | Electrophysiology |
23 | Data Interpretation, Statistical |
23 | Compulsive Behavior |
23 | Baclofen |
23 | Apoptosis Regulatory Proteins |
23 | Akathisia, Drug-Induced |
22 | Verbal Behavior |
22 | Task Performance and Analysis |
22 | Rest |
22 | Receptors, N-Methyl-D-Aspartate |
22 | Pyrrolidines |
22 | Proteins |
22 | Piperidines |
22 | Magnetics |
22 | Linkage Disequilibrium |
22 | Isometric Contraction |
22 | Glucosylceramidase |
22 | Feasibility Studies |
22 | Factor Analysis, Statistical |
22 | Diagnostic and Statistical Manual of Mental Disorders |
22 | DNA, Mitochondrial |
22 | Conversion Disorder |
22 | Blood Glucose |